Shattuck Labs (STTK) Chief Medical Officer reports 3,195-share Form 4 sale

Rhea-AI Filing Summary

Shattuck Labs Chief Medical Officer reports share disposition

Shattuck Labs, Inc.'s Chief Medical Officer, Arundathy N. Pandite, reported a transaction in the company’s common stock. On 01/25/2026, 3,195 shares of common stock were disposed of in a transaction coded "F" at a price of $4.15 per share. Following this transaction, Pandite beneficially owns 196,219 shares of Shattuck Labs common stock in direct ownership form.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pandite Arundathy N.

(Last) (First) (Middle)

C/O SHATTUCK LABS, INC.

500 W. 5TH STREET, SUITE 1200

(Street)

AUSTIN TX 78701

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Shattuck Labs, Inc. [ STTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/25/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/25/2026		F		3,195	D	$4.15	196,219	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Andrew R. Neill, Attorney-in-fact for Arundathy N. Pandite	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did STTK's Chief Medical Officer report?

Arundathy N. Pandite, Chief Medical Officer of Shattuck Labs, Inc. (STTK), reported disposing of 3,195 shares of common stock on 01/25/2026 in a transaction coded "F".

At what price were the Shattuck Labs (STTK) shares transacted?

The reported transaction in Shattuck Labs common stock occurred at a price of $4.15 per share.

How many STTK shares does Arundathy N. Pandite own after the transaction?

After the reported transaction, Arundathy N. Pandite beneficially owns 196,219 shares of Shattuck Labs common stock, held in direct ownership.

What is the role of the reporting person in Shattuck Labs (STTK)?

The reporting person, Arundathy N. Pandite, serves as the Chief Medical Officer of Shattuck Labs, Inc.

What does transaction code "F" indicate in the STTK Form 4 filing?

The Form 4 lists the transaction with code "F" for Shattuck Labs common stock. This is the code used in the report for the disposition of 3,195 shares at $4.15 per share.

Is the STTK insider transaction held directly or indirectly?

The Form 4 indicates the direct (D) ownership of the Shattuck Labs common stock, with 196,219 shares beneficially owned following the transaction.